CDP Site, Perth, Australia, Source: Hazer Group
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Hazer Group (ASX:HZR) shares surge after the company achieved first hydrogen and graphite production at its commercial demonstration plant in WA
  • HZR CEO and MD Glenn Corrie hailed the achievement as a significant milestone for the leading clean-tech developer
  • Throughout the first half of CY2024, Hazer plans to progressively scale up its operations, ensuring the safe execution of the performance testing program
  • HZR shares are up 15 per cent, trading at 69 cents at 12:25 pm AEDT

Hazer Group (ASX:HZR) shares have lifted about 15 per cent after the company achieved first hydrogen and graphite production at its commercial demonstration plant in Western Australia.

Hazer CEO and Managing Director Glenn Corrie hailed the achievement as a significant milestone for the leading clean-tech developer.

“This is a landmark achievement for Hazer, as we realise the successful start-up of our CDP and the production of low-cost, low-emissions hydrogen and graphitic carbon utilising our world-first pyrolysis technology,” he said.

“As the team strive towards extended continuous operation of the plant in 2024 we are excited to build on this momentum for the next scale-up of the technology with our global partners in key markets, including North America, Europe and Asia.”

Hazer plans to progressively scale up its operations throughout the first half of CY2024 to ensure the safe execution of the performance testing program.

The testing will focus on showcasing sustained operation at a commercial scale, contributing to Hazer’s global commercial project portfolio.

HZR shares were up 15 per cent, trading at 69 cents at 12:25 pm AEDT.

HZR by the numbers
More From The Market Online
Seaweed

Can you really get gold and silver out of seaweed? It turns out, yes you can

BPH Global is an interesting offering on the ASX: It's extracting precious metals from seaweeds cultivated…

Hollista Coltech sues ProImmune Director in WA court after US case dismissal

Malaysia-focused "premium grade collagen" and natural foods player Hollista Coltech (ASX:HCT) has had its shares suspended…
Human brain neurons

Neurizon finds positive results for lead drug in 3D brain model study

Neurizon Therapeutics Ltd has completed a study together with Tessara Therapeutics on the impact of NUZ-001…
Heart and lungs concept

Nanocap health tech provider Cardiex flat as ‘CONNEQT’ hits Apple Health

Cardie has remained flat on a happier Tuesday as its CONNEQT cardiovascular health software integrates with…